Results 11 to 20 of about 961,470 (198)

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

Journal of Clinical Oncology, 2022
PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not
T. Jelínek, R. Bezděková, D. Žihala, T. Ševčíková, A. Anilkumar Sithara, L. Pospisilova, S. Ševčíková, P. Polackova, M. Štork, Z. Knechtová, O. Venglar, V. Kapustová, T. Popková, L. Muroňová, Z. Chyra, M. Hrdinka, M. Šimíček, J. Garcés, N. Puig, M. Cedena, A. Jurczyszyn, J. Castillo, M. Penka, J. Radocha, M. Mateos, J. San-Miguel, B. Paiva, L. Pour, L. Říhová, R. Hájek   +29 more
semanticscholar   +1 more source

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Blood Cancer Journal, 2021
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease.
C. Fernández de Larrea, R. Kyle, L. Rosiñol, B. Paiva, M. Engelhardt, S. Usmani, J. Caers, W. Gonsalves, Fredrik H. Schjesvold, G. Merlini, Suzanne Lentzch, E. Ocio, L. Garderet, P. Moreau, P. Sonneveld, A. Badros, G. Gahrton, H. Goldschmidt, S. Tuchman, H. Einsele, B. Durie, B. Wirk, P. Musto, P. Hayden, M. Kaiser, J. Miguel, J. Bladé, S. Rajkumar, M. Mateos   +28 more
semanticscholar   +1 more source

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

Clinical and Translational Medicine, 2021
Background Relapsed/refractory (R/R) multiple myeloma (MM) patients and primary plasma cell leukemia (PCL) have an unfavorable prognosis and no effective treatment.
Chunrui Li, Wenyue Cao, Yimei Que, Qiuxiang Wang, Yi Xiao, Chaojiang Gu, Di Wang, Jue Wang, Lijun Jiang, Hao Xu, Jinhuan Xu, Xiaoxi Zhou, Z. Hong, Na Wang, Liang Huang, Shangkun Zhang, Liting Chen, X. Mao, M. Xiao, Wei Zhang, L. Meng, Yang Cao, Tongcun Zhang, Jian Li, Jianfeng Zhou   +24 more
semanticscholar   +1 more source

Update on primary plasma cell leukemia

Blood Research, 2022
Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell neoplasm developing in 0.5‒4% of patients with multiple myeloma (MM). The diagnostic criteria were recently revised from 20% to ≥5% of circulating plasma cells in peripheral blood ...
S. Jung, Je-Jung Lee
semanticscholar   +1 more source

A clinical perspective on plasma cell leukemia; current status and future directions

Blood Cancer Journal, 2021
Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed 20% of white blood cells or 2000/μL.
S. Tuazon, L. Holmberg, O. Nadeem, P. Richardson   +3 more
semanticscholar   +1 more source

PLASMA CELL LEUKEMIA [PDF]

Blood, 1946
Abstract A case of plasma cell leukemia is reported, together with a review of the literature, including a summary of the signs, symptoms, and laboratory findings usually present. The relationship of this leukemic state to ordinary plasmacytoma, a tumor of white cell origin, is discussed.
W T, MOSS, L V, ACKERMAN
openaire   +2 more sources

Plasma cell leukemia [PDF]

Blood Reviews, 2011
Plasma cell leukemia (PCL) is a rare, yet aggressive plasma cell (PC) neoplasm, variant of multiple myeloma (MM), characterized by high levels of PCs circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of MM (secondary PCL). Presenting signs and symptoms are similar to those seen
Flavio, Albarracin, Rafael, Fonseca
openaire   +2 more sources

Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.

Mayo Clinic proceedings, 2021
OBJECTIVE To evaluate the clinical outcomes of patients with primary plasma cell leukemia (pPCL) defined by 5% or greater clonal circulating plasma cells on peripheral blood smear and treated with novel agent induction therapies. PATIENTS AND METHODS A
B. Nandakumar, Shaji K. Kumar, A. Dispenzieri, F. Buadi, D. Dingli, M. Lacy, S. Hayman, P. Kapoor, N. Leung, A. Fonder, M. Hobbs, Y. Hwa, Eli Muchtar, R. Warsame, T. Kourelis, S. Russell, J. Lust, Yi Lin, M. Siddiqui, R. Go, D. Jevremovic, R. Kyle, M. Gertz, S. Rajkumar, W. Gonsalves   +24 more
semanticscholar   +1 more source

Plasma cell leukemia

Haematologica, 2010
Moria A. Gertz, Francis K. Buadi
doaj   +3 more sources

Hematopoietic Cell Transplantation Utilization and Outcomes for Primary Plasma Cell Leukemia in the Current Era

Leukemia, 2020
The outcomes of patients with primary plasma cell leukemia (pPCL) after undergoing hematopoietic cell transplantation (HCT) in the novel agent era are unknown.
B. Dhakal, Sagar S. Patel, S. Girnius, Lohith S. Bachegowda, R. Fraser, Omar Dávila, A. Kanate, Amer Assal, A. Hanbali, A. Bashey, A. Pawarode, C. Freytes, Cindy H Lee, D. Vesole, R. Cornell, G. Hildebrandt, H. Murthy, H. Lazarus, J. Černý, J. Yared, J. Schriber, J. Berdeja, K. Stockerl-Goldstein, K. Meehan, L. Holmberg, M. Solh, M. Díaz, M. Kharfan-Dabaja, N. Farhadfar, Q. Bashir, R. Munker, R. Olsson, R. Gale, Ruthlee-Lu Bayer, S. Seo, S. Chhabra, S. Hashmi, S. Badawy, T. Nishihori, W. Gonsalves, Y. Nieto, Y. Efebera, Shaji K. Kumar, N. Shah, M. Qazilbash, P. Hari, A. D’Souza   +46 more
semanticscholar   +1 more source